These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16940036)

  • 1. Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses.
    Healy B; Degruttola V
    Biostatistics; 2007 Apr; 8(2):438-52. PubMed ID: 16940036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining cross-sectional and prospective data methods to improve transition parameter estimation for characterizing the accumulation of HIV-1 drug resistance mutations.
    Healy B; De Gruttola V; Pagano M
    Biometrics; 2007 Sep; 63(3):742-50. PubMed ID: 17403101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accommodating uncertainty in a tree set for function estimation.
    Healy BC; DeGruttola VG; Hu C
    Stat Appl Genet Mol Biol; 2008; 7(1):Article5. PubMed ID: 18312210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
    Marcelin AG; Flandre P; de Mendoza C; Roquebert B; Peytavin G; Valer L; Wirden M; Abbas S; Katlama C; Soriano V; Calvez V
    Antivir Ther; 2007; 12(2):247-52. PubMed ID: 17503666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
    Liu J; Yue J; Wu S; Yan Y
    Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of continuous time hidden Markov models to the study of misclassified disease outcomes.
    Bureau A; Shiboski S; Hughes JP
    Stat Med; 2003 Feb; 22(3):441-62. PubMed ID: 12529874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
    Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S
    J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint modeling of progression of HIV resistance mutations measured with uncertainty and failure time data.
    Hu C; De Gruttola V
    Biometrics; 2007 Mar; 63(1):60-8. PubMed ID: 17447930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint modeling of longitudinal data and informative dropout time in the presence of multiple changepoints.
    Ghosh P; Ghosh K; Tiwari RC
    Stat Med; 2011 Mar; 30(6):611-26. PubMed ID: 21337357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.
    van Maarseveen NM; Wensing AM; de Jong D; Taconis M; Borleffs JC; Boucher CA; Nijhuis M
    J Infect Dis; 2007 Feb; 195(3):399-409. PubMed ID: 17205479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semiparametric estimation in a three-state duration-dependent Markov model from interval-censored observations with application to AIDS data.
    Frydman H
    Biometrics; 1995 Jun; 51(2):502-11. PubMed ID: 7662839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
    Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
    Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computing short-interval transition matrices of a discrete-time Markov chain from partially observed data.
    Charitos T; de Waal PR; van der Gaag LC
    Stat Med; 2008 Mar; 27(6):905-21. PubMed ID: 17579926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
    Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
    AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple augmentation for interval-censored data with measurement error.
    Song X; Ma S
    Stat Med; 2008 Jul; 27(16):3178-90. PubMed ID: 18040984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel drug resistance mutations in HIV: recognition and clinical relevance.
    Perno CF; Svicher V; Ceccherini-Silberstein F
    AIDS Rev; 2006; 8(4):179-90. PubMed ID: 17219733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The V118I mutation as a marker of advanced HIV infection and disease progression.
    Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
    Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes.
    SPREAD programme
    AIDS; 2008 Mar; 22(5):625-35. PubMed ID: 18317004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.
    King MS; Rode R; Cohen-Codar I; Calvez V; Marcelin AG; Hanna GJ; Kempf DJ
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3067-74. PubMed ID: 17576846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.